{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["aristolochic acid A", "bioassay evaluation", "dual ETA/ETB receptor", "molecular docking", "pharmacophore"]], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "26999111", "DateCompleted": {"Year": "2017", "Month": "01", "Day": "16"}, "DateRevised": {"Year": "2019", "Month": "01", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "03", "Day": "16"}], "ELocationID": ["389", "10.3390/ijms17030389"], "Language": ["eng"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "17", "Issue": "3", "PubDate": {"Year": "2016", "Month": "Mar", "Day": "16"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Discovery of Dual ETA/ETB Receptor Antagonists from Traditional Chinese Herbs through in Silico and in Vitro Screening.", "Pagination": {"StartPage": "389", "MedlinePgn": "389"}, "Abstract": {"AbstractText": ["Endothelin-1 receptors (ETAR and ETBR) act as a pivotal regulator in the biological effects of ET-1 and represent a potential drug target for the treatment of multiple cardiovascular diseases. The purpose of the study is to discover dual ETA/ETB receptor antagonists from traditional Chinese herbs. Ligand- and structure-based virtual screening was performed to screen an in-house database of traditional Chinese herbs, followed by a series of in vitro bioassay evaluation. Aristolochic acid A (AAA) was first confirmed to be a dual ETA/ETB receptor antagonist based intracellular calcium influx assay and impedance-based assay. Dose-response curves showed that AAA can block both ETAR and ETBR with IC50 of 7.91 and 7.40 \u03bcM, respectively. Target specificity and cytotoxicity bioassay proved that AAA is a selective dual ETA/ETB receptor antagonist and has no significant cytotoxicity on HEK293/ETAR and HEK293/ETBR cells within 24 h. It is a feasible and effective approach to discover bioactive compounds from traditional Chinese herbs using in silico screening combined with in vitro bioassay evaluation. The structural characteristic of AAA for its activity was especially interpreted, which could provide valuable reference for the further structural modification of AAA."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Key Lab of Traditional Chinese Medicine (TCM) Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China. wangxing@ccmu.edu.cn."}], "LastName": "Wang", "ForeName": "Xing", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of TCM-Information Engineer of State Administration of TCM, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China. zhangyuxinwjzy@163.com."}], "LastName": "Zhang", "ForeName": "Yuxin", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of TCM-Information Engineer of State Administration of TCM, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China. sdliuqing17@tom.com."}], "LastName": "Liu", "ForeName": "Qing", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beijing Key Lab of Traditional Chinese Medicine (TCM) Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China. azxccmu@163.com."}], "LastName": "Ai", "ForeName": "Zhixin", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of TCM-Information Engineer of State Administration of TCM, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China. collean_zhang@163.com."}], "LastName": "Zhang", "ForeName": "Yanling", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, Capital Normal University, Beijing 100069, China. cnuxiangyh@163.com."}], "LastName": "Xiang", "ForeName": "Yuhong", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of TCM-Information Engineer of State Administration of TCM, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China. yjqiao@bucm.edu.cn."}], "LastName": "Qiao", "ForeName": "Yanjiang", "Initials": "Y"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Aristolochic Acids"}, {"RegistryNumber": "0", "NameOfSubstance": "EDNRB protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Endothelin A Receptor Antagonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Endothelin B Receptor Antagonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptor, Endothelin A"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptor, Endothelin B"}, {"RegistryNumber": "94218WFP5T", "NameOfSubstance": "aristolochic acid I"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Aristolochic Acids"}, {"QualifierName": [], "DescriptorName": "Computer Simulation"}, {"QualifierName": [], "DescriptorName": "Drug Evaluation, Preclinical"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Endothelin A Receptor Antagonists"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Endothelin B Receptor Antagonists"}, {"QualifierName": [], "DescriptorName": "HEK293 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug effects"], "DescriptorName": "Receptor, Endothelin A"}, {"QualifierName": ["drug effects"], "DescriptorName": "Receptor, Endothelin B"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411\u2013415. doi: 10.1038/332411a0.", "ArticleIdList": ["10.1038/332411a0", "2451132"]}, {"Citation": "Stauffer B.L., Diehl K.J., Dow C.A., Templeton D.L., Greiner J.J., DeSouza C.A. Chronic nebivolol treatment suppresses endothelin-1-mediated vasoconstrictor tone in adults with elevated blood pressure. Circulation. 2014;130:A15536\u2013A15536.", "ArticleIdList": ["PMC4871319", "27113048"]}, {"Citation": "Vaneckov\u00e1 I., Dobe\u0161ov\u00e1 Z., Kune\u0161 J., Vernerov\u00e1 Z., Zicha J. Endothelin a receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in ren-2 transgenic rats fed a high-salt diet. J. Hypertens. 2015;33:161\u2013169. doi: 10.1097/HJH.0000000000000357.", "ArticleIdList": ["10.1097/HJH.0000000000000357", "25255392"]}, {"Citation": "Weng C.-M., Yu C.-C., Kuo M.-L., Chen B.-C., Lin C.-H. Endothelin-1 induces connective tissue growth factor expression in human lung fibroblasts by ETAR-dependent JNK/AP-1 pathway. Biochem. Pharmacol. 2014;88:402\u2013411. doi: 10.1016/j.bcp.2014.01.030.", "ArticleIdList": ["10.1016/j.bcp.2014.01.030", "24486572"]}, {"Citation": "Ramseyer V.D., Gonzalez-Vicente A., Carretero O.A., Garvin J.L. Angiotensin II-induced hypertension blunts thick ascending limb NO production by reducing NO synthase 3 expression and enhancing threonine 495 phosphorylation. Am. J. Physiol. Renal Physiol. 2015;308:F149\u2013F156. doi: 10.1152/ajprenal.00279.2014.", "ArticleIdList": ["10.1152/ajprenal.00279.2014", "PMC4338926", "25377910"]}, {"Citation": "Bender S.B., Beer V.J., Tharp D.L., Deel E.D., Bowles D.K., Duncker D.J., Laughlin M.H., Merkus D. Reduced contribution of endothelin to the regulation of systemic and pulmonary vascular tone in severe familial hypercholesterolaemia. J. Physiol. 2014;592:1757\u20131769. doi: 10.1113/jphysiol.2013.267351.", "ArticleIdList": ["10.1113/jphysiol.2013.267351", "PMC4001750", "24421352"]}, {"Citation": "Rodriguez-Pascual F., Busnadiego O., Lagares D., Lamas S. Role of endothelin in the cardiovascular system. Pharmacol. Res. 2011;63:463\u2013472. doi: 10.1016/j.phrs.2011.01.014.", "ArticleIdList": ["10.1016/j.phrs.2011.01.014", "21296157"]}, {"Citation": "Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730\u2013732. doi: 10.1038/348730a0.", "ArticleIdList": ["10.1038/348730a0", "2175396"]}, {"Citation": "Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732\u2013735. doi: 10.1038/348732a0.", "ArticleIdList": ["10.1038/348732a0", "2175397"]}, {"Citation": "Gilbert J.S., Gillham H.E., Regal J.F. Down but not out an emerging role for the B-type endothelin receptor in placental ischemia\u2013induced hypertension. Hypertension. 2014;64:461\u2013462. doi: 10.1161/HYPERTENSIONAHA.114.03477.", "ArticleIdList": ["10.1161/HYPERTENSIONAHA.114.03477", "PMC4134361", "24914197"]}, {"Citation": "Ambrosini S., Sarchielli E., Comeglio P., Porfirio B., Gallina P., Morelli A., Vannelli G.B. Fibroblast growth factor and endothelin-1 receptors mediate the response of human striatal precursor cells to hypoxia. Neuroscience. 2015;289:123\u2013133. doi: 10.1016/j.neuroscience.2014.12.073.", "ArticleIdList": ["10.1016/j.neuroscience.2014.12.073", "25595970"]}, {"Citation": "Schinzari F., Iantorno M., Campia U., Mores N., Rovella V., Tesauro M., Di Daniele N., Cardillo C. Vasodilator responses and endothelin-dependent vasoconstriction in metabolically healthy obesity and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 2015;309:E787\u2013E792. doi: 10.1152/ajpendo.00278.2015.", "ArticleIdList": ["10.1152/ajpendo.00278.2015", "PMC4628941", "26374766"]}, {"Citation": "Cutolo M., Ruaro B., Pizzorni C., Ravera F., Smith V., Zampogna G., Paolino S., Seriolo B., Cimmino M., Sulli A. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J. Rheumatol. 2014;41:881\u2013886. doi: 10.3899/jrheum.131284.", "ArticleIdList": ["10.3899/jrheum.131284", "24692525"]}, {"Citation": "Cai J., Liu L., Hong K.H., Wang P., Li L., Cao M., Sun C., Wu X., Zong X., Chen J., et al. Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity. Bioorgan. Med. Chem. 2015;23:657\u2013667. doi: 10.1016/j.bmc.2015.01.003.", "ArticleIdList": ["10.1016/j.bmc.2015.01.003", "25614116"]}, {"Citation": "Akamata K., Asano Y., Yamashita T., Noda S., Taniguchi T., Takahashi T., Ichimura Y., Toyama T., Trojanowska M., Sato S. Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability. Arthritis Rheumatol. 2015;67:1335\u20131344. doi: 10.1002/art.39062.", "ArticleIdList": ["10.1002/art.39062", "PMC4784268", "25707716"]}, {"Citation": "Howell G.R., MacNicoll K.H., Braine C.E., Soto I., Macalinao D.G., Sousa G.L., John S.W. Combinatorial targeting of early pathways profoundly inhibits neurodegeneration in a mouse model of glaucoma. Neurobiol. Dis. 2014;71:44\u201352. doi: 10.1016/j.nbd.2014.07.016.", "ArticleIdList": ["10.1016/j.nbd.2014.07.016", "PMC4319373", "25132557"]}, {"Citation": "Saleh L., Danser J.A., van den Meiracker A.H. Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment. Curr. Opin. Nephrol. Hypertens. 2016;25:94\u201399. doi: 10.1097/MNH.0000000000000197.", "ArticleIdList": ["10.1097/MNH.0000000000000197", "26717314"]}, {"Citation": "Anguiano L., Riera M., Pascual J., Soler M.J. Endothelin blockade in diabetic kidney disease. J. Clin. Med. 2015;4:1171\u20131192. doi: 10.3390/jcm4061171.", "ArticleIdList": ["10.3390/jcm4061171", "PMC4484993", "26239552"]}, {"Citation": "Teoh J.P., Park K.M., Wang Y., Hu Q., Kim S., Wu G., Huang S., Maihle N., Kim I.M. Endothelin-1/endothelin a receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis. Cell. Signal. 2014;26:2885\u20132895. doi: 10.1016/j.cellsig.2014.08.024.", "ArticleIdList": ["10.1016/j.cellsig.2014.08.024", "PMC4254323", "25194819"]}, {"Citation": "Rodriguez-Pascual F., Busnadiego O., Gonzalez-Santamaria J. The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases? Life Sci. 2014;118:156\u2013164. doi: 10.1016/j.lfs.2013.12.024.", "ArticleIdList": ["10.1016/j.lfs.2013.12.024", "24378671"]}, {"Citation": "Kopec G., Tyrka A., Miszalski-Jamka T., Mikolajczyk T., Waligora M., Guzik T., Podolec P. Changes in exercise capacity and cardiac performance in a series of patients with eisenmenger\u2018s syndrome transitioned from selective to dual endothelin receptor antagonist. Heart Lung Circ. 2012;21:671\u2013678. doi: 10.1016/j.hlc.2012.06.013.", "ArticleIdList": ["10.1016/j.hlc.2012.06.013", "22819097"]}, {"Citation": "Nielsen E.A., Sun M., Honjo O., Hjortdal V.E., Redington A.N., Friedberg M.K. Dual endothelin receptor blockade abrogates right ventricular remodeling and biventricular fibrosis in isolated elevated right ventricular afterload. PLoS ONE. 2016;11:389. doi: 10.1371/journal.pone.0146767.", "ArticleIdList": ["10.1371/journal.pone.0146767", "PMC4713098", "26765263"]}, {"Citation": "Bolli M.H., Boss C., Binkert C., Buchmann S., Bur D., Hess P., Iglarz M., Meyer S., Rein J., Rey M., et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N\u2032-p ropylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist. J. Med. Chem. 2012;55:7849\u20137861. doi: 10.1021/jm3009103.", "ArticleIdList": ["10.1021/jm3009103", "22862294"]}, {"Citation": "Li C.X., Ding L.Y., Qing L.I., Zhu X.H., Fang D., Lei H.A.O. Experimental study on effect of Xin Guanxin Suhe drop pill on acute myocardial ischemia. Tradit. Chin. Drug Res. Clin. Pharmacol. 2008;19:109\u2013111."}, {"Citation": "Wang X., Ren Z., He Y., Xiang Y., Zhang Y., Qiao Y. A combination of pharmacophore modeling, molecular docking and virtual screening for inos inhibitors from chinese herbs. BioMed. Mater. Eng. 2014;24:1315\u20131322.", "ArticleIdList": ["24212027"]}, {"Citation": "Wu H., Wacker D., Mileni M., Katritch V., Han G.W., Vardy E., Liu W., Thompson A.A., Huang X.P., Carroll F.I., et al. Structure of the human \u03ba-opioid receptor in complex with JDTic. Nature. 2012;485:327\u2013332. doi: 10.1038/nature10939.", "ArticleIdList": ["10.1038/nature10939", "PMC3356457", "22437504"]}, {"Citation": "Kuntal B.K., Aparoy P., Reddanna P. Easymodeller: A graphical interface to modeller. BMC Res. Notes. 2010;3:389. doi: 10.1186/1756-0500-3-226.", "ArticleIdList": ["10.1186/1756-0500-3-226", "PMC2936912", "20712861"]}, {"Citation": "Krystek S.R., Jr., Patel P.S., Rose P.M., Fisher S.M., Kienzle B.K., Lach D.A., Liu E.C., Lynch J.S., Novotny J., Webb M.L. Mutation of peptide binding site in transmembrane region of a g protein-coupled receptor accounts for endothelin receptor subtype selectivity. J. Biol. Chem. 1994;269:12383\u201312386.", "ArticleIdList": ["8175640"]}, {"Citation": "Adachi M., Furuichi Y., Miyamoto C. Identification of a ligand-binding site of the human endothelin-a receptor and specific regions required for ligand selectivity. FEBS. 1994;220:37\u201343. doi: 10.1111/j.1432-1033.1994.tb18596.x.", "ArticleIdList": ["10.1111/j.1432-1033.1994.tb18596.x", "8119297"]}, {"Citation": "Rose P.M., Krystek S.R., Jr., Patel P.S., Liu E.C., Lynch J.S., Lach D.A., Fisher S.M., Webb M.L. Aspartate mutation distinguishes eta but not etb receptor subtype-selective ligand binding while abolishing phospholipase C activation in both receptors. FEBS Lett. 1995;361:243\u2013249. doi: 10.1016/0014-5793(95)00164-5.", "ArticleIdList": ["10.1016/0014-5793(95)00164-5", "7698331"]}, {"Citation": "Clozel M., Breu V., Gray G.A., Kalina B., Loffler B.M., Burri K., Cassal J.M., Hirth G., Muller M., Neidhart W., et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 1994;270:228\u2013235.", "ArticleIdList": ["8035319"]}, {"Citation": "Angalaparameswari S., Saleem T.M., Alagusundaram M., Ramkanth S., Thiruvengadarajan V., Gnanaprakash K., Chetty C.M., Pratheesh G. Anti-microbial activity of aristolochic acid from root of Aristolochia bracteata retz. Inter. J. Bio. Life Sci. 2012;8:2\u20134."}, {"Citation": "Suliman Mohamed M., Timan Idriss M., Khedr A.I., Abd AlGadir H., Takeshita S., Shah M.M., Ichinose Y., Maki T. Activity of Aristolochia bracteolata against Moraxella catarrhalis. Int. J. Bacteriol. 2014;2014:481686.", "ArticleIdList": ["PMC4745564", "26904734"]}, {"Citation": "Loiko E.N., Samal A.B., Shulyakovskaya S.M. H2O2-induced platelet aggregation and increase in intracellular Ca2+ concentration are blocked by inhibitors of intracellular signaling. Biochemistry. 2003;68:1210\u20131216. doi: 10.1023/B:BIRY.0000009135.85883.65.", "ArticleIdList": ["10.1023/B:BIRY.0000009135.85883.65", "14640963"]}, {"Citation": "Iuliano L., Pedersen J.Z., Pratico D., Rotilio G., Violi F. Role of hydroxyl radicals in the activation of human platelets. FEBS. 1994;221:695\u2013704. doi: 10.1111/j.1432-1033.1994.tb18782.x.", "ArticleIdList": ["10.1111/j.1432-1033.1994.tb18782.x", "8174549"]}, {"Citation": "Shen M.Y., Liu C.L., Hsiao G., Liu C.Y., Lin K.H., Chou D.S., Sheu J.R. Involvement of p38 MAPK phosphorylation and nitrate formation in aristolochic acid-mediated antiplatelet activity. Planta Med. 2008;74:1240\u20131245. doi: 10.1055/s-2008-1074560.", "ArticleIdList": ["10.1055/s-2008-1074560", "18563667"]}, {"Citation": "Kowalczyk A., Kleniewska P., Kolodziejczyk M., Skibska B., Goraca A. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch. Immunol. Ther. Exp. (Warsz) 2015;63:41\u201352. doi: 10.1007/s00005-014-0310-1.", "ArticleIdList": ["10.1007/s00005-014-0310-1", "PMC4289534", "25288367"]}, {"Citation": "Ihara M., Ishikawa K., Fukuroda T., Saeki T., Funabashi K., Fukami T., Suda H., Yano M. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J. Cardiovasc. Pharmacol. 1992;20(Suppl 12):S11\u2013S14. doi: 10.1097/00005344-199204002-00005.", "ArticleIdList": ["10.1097/00005344-199204002-00005", "1282942"]}, {"Citation": "Poon S.L., Huang M.N., Choo Y., McPherson J.R., Yu W., Heng H.L., Gan A., Myint S.S., Siew E.Y., Ler L.D., et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med. 2015;7:38. doi: 10.1186/s13073-015-0161-3.", "ArticleIdList": ["10.1186/s13073-015-0161-3", "PMC4443665", "26015808"]}, {"Citation": "Huang T.C., Chen S.M., Li Y.C., Lee J.A. Increased renal semicarbazide-sensitive amine oxidase activity and methylglyoxal levels in aristolochic acid-induced nephrotoxicity. Life Sci. 2014;114:4\u201311. doi: 10.1016/j.lfs.2014.07.034.", "ArticleIdList": ["10.1016/j.lfs.2014.07.034", "25107330"]}, {"Citation": "Zhao Y.Y., Tang D.D., Chen H., Mao J.R., Bai X., Cheng X.H., Xiao X.Y. Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. Bioanalysis. 2015;7:685\u2013700. doi: 10.4155/bio.14.309.", "ArticleIdList": ["10.4155/bio.14.309", "25871586"]}, {"Citation": "Bolli M.H., Marfurt J., Grisostomi C., Boss C., Binkert C., Hess P., Treiber A., Thorin E., Morrison K., Buchmann S., et al. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J. Med. Chem. 2004;47:2776\u20132795. doi: 10.1021/jm031115r.", "ArticleIdList": ["10.1021/jm031115r", "15139756"]}, {"Citation": "Takahashi H., Ohtake N., Sakamoto T., Iino T., Kawanishi N., Nakamura M., Yoshizumi T., Niiyama K., Ozaki S., Okada H., et al. Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines. Bioorgan. Med. Chem. Lett. 2004;14:1503\u20131507. doi: 10.1016/j.bmcl.2004.01.008.", "ArticleIdList": ["10.1016/j.bmcl.2004.01.008", "15006391"]}, {"Citation": "Liu G., Kozmina N.S., Winn M., von Geldern T.W., Chiou W.J., Dixon D.B., Nguyen B., Marsh K.C., Opgenorth T.J. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ETB antagonists containing a diphenylmethylamine acetamide side chain. J. Med. Chem. 1999;42:3679\u20133689. doi: 10.1021/jm990171i.", "ArticleIdList": ["10.1021/jm990171i", "10479299"]}, {"Citation": "Neidhart W., Breu V., Burri K., Clozel M., Hirth G., Klinkhammer U., Giller T., Ramuz H. Discovery of Ro 48\u20135695: A potent mixed endothelin receptor antagonist optimized from bosentan. Bioorgan. Med. Chem. Lett. 1997;7:2223\u20132228. doi: 10.1016/S0960-894X(97)00400-9.", "ArticleIdList": ["10.1016/S0960-894X(97)00400-9"]}, {"Citation": "Niiyama K., Takahashi H., Nagase T., Kojima H., Amano Y., Katsuki K., Yamakawa T., Ozaki S., Ihara M., Yano M., et al. Structure-activity relationships of 2-substituted 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids as a novel class of endothelin receptor antagonists. Bioorgan. Med. Chem. Lett. 2002;12:3041\u20133045. doi: 10.1016/S0960-894X(02)00663-7.", "ArticleIdList": ["10.1016/S0960-894X(02)00663-7", "12372497"]}, {"Citation": "Jae H.S., Winn M., Dixon D.B., Marsh K.C., Nguyen B., Opgenorth T.J., von Geldern T.W. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists. J. Med. Chem. 1997;40:3217\u20133227. doi: 10.1021/jm970101g.", "ArticleIdList": ["10.1021/jm970101g", "9379441"]}, {"Citation": "Von Geldern T.W., Tasker A.S., Sorensen B.K., Winn M., Szczepankiewicz B.G., Dixon D.B., Chiou W.J., Wang L., Wessale J.L., Adler A., et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ETB selectivity. J. Med. Chem. 1999;42:3668\u20133678. doi: 10.1021/jm990170q.", "ArticleIdList": ["10.1021/jm990170q", "10479298"]}, {"Citation": "Bolli M.H., Boss C., Clozel M., Fischli W., Hess P., Weller T. The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists. Bioorgan. Med. Chem. Lett. 2003;13:955\u2013959. doi: 10.1016/S0960-894X(02)01084-3.", "ArticleIdList": ["10.1016/S0960-894X(02)01084-3", "12617929"]}, {"Citation": "Fukami T., Yamakawa T., Niiyama K., Kojima H., Amano Y., Kanda F., Ozaki S., Fukuroda T., Ihara M., Yano M., et al. Synthesis and structure-activity relationships of 2-substituted d-tryptophan-containing peptidic endothelin receptor antagonists: Importance of the C-2 substituent of the d-tryptophan residue for endothelin A and B receptor subtype selectivity. J. Med. Chem. 1996;39:2313\u20132330. doi: 10.1021/jm9600914.", "ArticleIdList": ["10.1021/jm9600914", "8691426"]}, {"Citation": "Ishizuka N., Matsumura K., Sakai K., Fujimoto M., Mihara S., Yamamori T. Structure-activity relationships of a novel class of endothelin-a receptor antagonists and discovery of potent and selective receptor antagonist, 2-(benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2H-chromene-3-carbox ylic acid (S-1255). 1. Study on structure-activity relationships and basic structure crucial for ETA antagonism. J. Med. Chem. 2002;45:2041\u20132055.", "ArticleIdList": ["11985472"]}, {"Citation": "Patel H.J., Olgun N., Lengyel I., Reznik S., Stephani R.A. Synthesis and pharmacological activity of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acids as selective ETA antagonists. Bioorgan. Med. Chem. Lett. 2010;20:6840\u20136844. doi: 10.1016/j.bmcl.2010.08.074.", "ArticleIdList": ["10.1016/j.bmcl.2010.08.074", "20932745"]}, {"Citation": "Patt W.C., Edmunds J.J., Repine J.T., Berryman K.A., Reisdorph B.R., Lee C., Plummer M.S., Shahripour A., Haleen S.J., Keiser J.A., et al. Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists. J. Med. Chem. 1997;40:1063\u20131074. doi: 10.1021/jm9606507.", "ArticleIdList": ["10.1021/jm9606507", "9089328"]}, {"Citation": "Arooj M., Sakkiah S., Cao G., Lee K.W. An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes. PLoS ONE. 2013;8:389. doi: 10.1371/journal.pone.0060470.", "ArticleIdList": ["10.1371/journal.pone.0060470", "PMC3618229", "23577115"]}, {"Citation": "Wang X., Xiang Y., Ren Z., Zhang Y., Qiao Y. Rational questing for inhibitors of endothelin converting enzyme-1 from salvia miltiorrhiza by combining ligand-and structure-based virtual screening. Can. J. Chem. 2013;91:448\u2013456. doi: 10.1139/cjc-2012-0523.", "ArticleIdList": ["10.1139/cjc-2012-0523"]}, {"Citation": "McGinnis S., Madden T.L. BLAST: At the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res. 2004;32:W20\u2013W25. doi: 10.1093/nar/gkh435.", "ArticleIdList": ["10.1093/nar/gkh435", "PMC441573", "15215342"]}, {"Citation": "Eswar N., John B., Mirkovic N., Fiser A., Ilyin V.A., Pieper U., Stuart A.C., Marti-Renom M.A., Madhusudhan M.S., Yerkovich B., et al. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res. 2003;31:3375\u20133380. doi: 10.1093/nar/gkg543.", "ArticleIdList": ["10.1093/nar/gkg543", "PMC168950", "12824331"]}, {"Citation": "Sali A. Comparative protein modeling by satisfaction of spatial restraints. Mol. Med. Today. 1995;1:270\u2013277. doi: 10.1107/S0108767396095578.", "ArticleIdList": ["10.1107/S0108767396095578", "9415161"]}, {"Citation": "Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. Procheck: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993;26:283\u2013291. doi: 10.1107/S0021889892009944.", "ArticleIdList": ["10.1107/S0021889892009944"]}, {"Citation": "Colovos C., Yeates T.O. Verification of protein structures: Patterns of nonbonded atomic interactions. Protein Sci. 1993;2:1511\u20131519. doi: 10.1002/pro.5560020916.", "ArticleIdList": ["10.1002/pro.5560020916", "PMC2142462", "8401235"]}, {"Citation": "Dai Z.R., Ai C.Z., Ge G.B., He Y.Q., Wu J.J., Wang J.Y., Man H.Z., Jia Y., Yang L. A mechanism-based model for the prediction of the metabolic sites of steroids mediated by cytochrome P450 3A4. Int. J. Mol. Sci. 2015;16:14677\u201314694. doi: 10.3390/ijms160714677.", "ArticleIdList": ["10.3390/ijms160714677", "PMC4519866", "26133240"]}, {"Citation": "Xie H., Chen L., Zhang J., Xie X., Qiu K., Fu J. A combined pharmacophore modeling, 3D QSAR and virtual screening studies on imidazopyridines as B-Raf inhibitors. Int. J. Mol. Sci. 2015;16:12307\u201312323. doi: 10.3390/ijms160612307.", "ArticleIdList": ["10.3390/ijms160612307", "PMC4490445", "26035757"]}, {"Citation": "Spitzer R., Jain A.N. Surflex-dock: Docking benchmarks and real-world application. J. Comput. Aided Mol. Des. 2012;26:687\u2013699. doi: 10.1007/s10822-011-9533-y.", "ArticleIdList": ["10.1007/s10822-011-9533-y", "PMC3398190", "22569590"]}, {"Citation": "Ishikawa K., Fukami T., Nagase T., Fujita K., Hayama T., Niiyama K., Mase T., Ihara M., Yano M. Cyclic pentapeptide endothelin antagonists with high ETA selectivity. Potency- and solubility-enhancing modifications. J. Med. Chem. 1992;35:2139\u20132142. doi: 10.1021/jm00089a028.", "ArticleIdList": ["10.1021/jm00089a028", "1317926"]}, {"Citation": "Okada M., Nishikibe M. BQ-788, a selective endothelin ETB receptor antagonist. Cardiovasc. Drug Rev. 2002;20:53\u201366. doi: 10.1111/j.1527-3466.2002.tb00082.x.", "ArticleIdList": ["10.1111/j.1527-3466.2002.tb00082.x", "12070534"]}], "ReferenceList": []}], "History": [{"Year": "2016", "Month": "1", "Day": "23"}, {"Year": "2016", "Month": "2", "Day": "25"}, {"Year": "2016", "Month": "3", "Day": "4"}, {"Year": "2016", "Month": "3", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "3", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "1", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "3", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["26999111", "PMC4813245", "10.3390/ijms17030389", "ijms17030389"]}}], "PubmedBookArticle": []}